Alzheimer's Disease NeuroImaging Initiative (ADNI)


This large multi-site project aims to define the rate of progression of mild cognitive impairment and Alzheimer's disease and to develop improved methodologies including biomarkers for AD clinical trials. It is a non-randomized natural history non-treatment study, which enrolls cognitively normal subjects as well as those with mild cognitive impairment (MCI) and mild Alzheimer's disease (AD). Enrolled subjects should be between 55-90 years of age, have a study partner able to provide an independent evaluation of functioning, and will speak either English or Spanish fluently. All subjects must be willing and able to undergo all test procedures including detailed cognitive testing, neuroimaging, lumbar punctures and blood draws. For more information, please call Naira Goukasian at (310) 794-3211 or send an email to This email address is being protected from spambots. You need JavaScript enabled to view it..

Sponsors: ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., and Wyeth, as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration.
Principal Investigator: Michael Weiner, MD, UCSF
Co-Investigator: Liana Apostolova, MD, MSCR

Contact: Naira Goukasian at (310) 794-3211 or This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.